Lisata Therapeutics, Inc. (Nasdaq: LSTA) disclosed in a regulatory filing on July 17, 2026, that it has amended the terms of its pending acquisition by Kuva Labs Inc., extending the deadline to close the transaction. The amendment pushes the so-called Outside Date from July 17, 2026 to July 21, 2026, a four-day extension that suggests the parties are close to satisfying the remaining conditions to complete the merger.
The original Agreement and Plan of Merger, dated March 6, 2026, set a termination date after which either party could walk away from the deal if it had not yet closed. The brief extension, formalized in an amendment signed on July 16, indicates that the companies are working through final steps but needed additional time beyond the original cutoff. The amendment was entered into by Lisata, Kuva Labs Inc. (the parent entity), and Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs formed to execute the acquisition.
The merger is structured as a tender offer, through which Kuva Labs is seeking to acquire outstanding shares of Lisata common stock. A tender offer statement on Schedule TO and a related Solicitation/Recommendation Statement on Schedule 14D-9 have been filed with the Securities and Exchange Commission. Lisata continues to direct shareholders to those documents for the full terms and conditions of the offer.
The filing does not disclose the specific reasons for the delay or what conditions remain outstanding. However, extending an outside date by only four days, rather than a longer period, typically signals that the parties believe resolution is imminent. The company did not announce any changes to the economic terms of the deal or to the tender offer price.
Lisata Therapeutics, a biopharmaceutical company focused on developing therapies for advanced solid tumors, has been navigating a period of financial constraint. Its most recent quarterly filing indicated that ongoing viability depends on new funding and the completion of the Kuva Labs acquisition. The merger represents a significant corporate event for the company, and the approaching deadline has drawn scrutiny. In late June 2026, a shareholder rights law firm announced it was investigating the company on behalf of investors concerning disclosures related to the acquisition financing, highlighting the sensitivity around the deal's completion.
The amendment itself is a brief document, incorporated by reference into the 8-K filing, and does not modify other material provisions of the merger agreement. Investors and security holders can obtain copies of the tender offer materials and the Solicitation/Recommendation Statement free of charge from the SEC's website or from the company's investor relations page.